ICCM Stock Catalyst: IceCure Medical Ltd. Highlights ProSense™ Cryoablation Expansion in Brazil

Jul 6, 2026 · 8:11am ET

Follows FDA clearance for breast cancer treatment.

Max move

+47.9%

High of day $7.87

Sparker timei

8:11am ET

ICCM · Jul 6, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

IceCure Medical Ltd. (Nasdaq: ICCM) announced the expanding commercial adoption of its ProSense™ Cryoablation system in Brazil. This announcement follows the FDA clearance for the use of ProSense™ in treating breast cancer.

The company did not provide specific figures or timelines for the expansion but emphasized the growing acceptance of its technology in the Brazilian market.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time ICCM sparks.

Download Sniper App →

Catch the next ICCM-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →